Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TACR2 | P21452 | 6/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | IL1RN | P18510 | 1/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7543753 | 0.89 | GAA (0.49) | GAAKMT2AEGFRALDH1A1MAPT | |
| SCHEMBL7428800 | 0.86 | CACNA1B (0.56) | TACR2CTSLCTSKCTSS | |
| SCHEMBL7341217 | 0.85 | TACR2 (0.50) | KMT2AALDH1A1MAPTTACR2L3MBTL1 | |
| SCHEMBL7344537 | 0.84 | TACR2 (0.64) | TACR2 | |
| SCHEMBL7425378 | 0.81 | GAA (0.53) | GAAKMT2AEGFRALDH1A1MAPT | |
| SCHEMBL7547521 | 0.81 | KMT2A (0.48) | GAAKMT2AEGFRALDH1A1MAPT | |
| SCHEMBL7544107 | 0.79 | L3MBTL1 (0.49) | LTA4HL3MBTL1RAB9ASMN1; SMN2IL1RN | |
| SCHEMBL7541485 | 0.79 | LTA4H (0.50) | CTSLCTSKLTA4HRAB9ASMN1; SMN2 | |
| SCHEMBL7542844 | 0.79 | LTA4H (0.47) | LTA4HRAB9ASMN1; SMN2IL1RNERAP2 | |
| Leucine SCHEMBL1406209 | 0.79 | CTSS (0.54) | TACR2CTSLPOLBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6362174-B1 | ANALGESICS, ANTIISCHEMIC AGENTS, ANTIEOILEPTIC AGENTS | WARNER-LAMBERT COMPANY | 2002-03-26 | — | — | US | claimed |
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | RAFFERTY MICHAEL FRANCIS (US) | 2002-03-07 | — | — | US | claimed |
| US-6316440-B1 | TREATMENT OF STROKE, HEAD TRAUMA, CEREBRAL ISCHEMIA, PAIN AND EPILEPSY | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | claimed |
| US-6362174-B1 | ANALGESICS, ANTIISCHEMIC AGENTS, ANTIEOILEPTIC AGENTS | WARNER-LAMBERT COMPANY | 2002-03-26 | — | — | US | disclosed |
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | RAFFERTY MICHAEL FRANCIS (US) | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | CACNA1E, RYR1, CACNA1B | GAA 4740/4885KMT2A 2402/4885EGFR 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.